Skip to main content

3-V Biosciences Appoints Dr. George W.Kemble, PhD, as Chief Scientific Officer

By 08/2011May 9th, 2023No Comments

Menlo Park, California, August 15, 2011. 3-V Biosciences, Inc. announced today the appointment of Dr. George W. Kemble, PhD as Chief Scientific Officer.

“We are very pleased to have George as the newest member of the 3-V senior management team,” said Merdad V. Parsey, MD, PhD, 3-V’s Chief Executive Officer. “George’s extensive experience in drug discovery and development, as well as virology and host cell biology, brings additional strength to the 3-V team and will further our efforts in this novel area.”

Prior to joining 3-V Biosciences, Dr. Kemble was with MedImmune, Inc., a subsidiary of Astra Zeneca PLC, where he most recently served as Senior Vice President of R&D and Head of Research. During his tenure, Dr. Kemble was responsible for the research and development of multiple products, including the successful launch of FluMist®, the first innovation in influenza vaccines in over 60 years. The research organization for which he was responsible included over 700 scientists in Maryland, California and Cambridge, England, with expertise in research biology, lead generation and translational science in the areas of infectious diseases, oncology, inflammatory, respiratory, autoimmune diseases, neuroscience, cardiovascular and gastrointestinal indications. Dr. Kemble began his research career as a staff scientist at Aviron, which was later acquired by MedImmune. Dr. Kemble received a BS from the University of Santa Clara and a PhD from Stanford University and did his post doctoral training at UCSF, where he worked on a number of different human viruses.

“I’m very excited by the important projects we have in front of us,” said Dr. Kemble. “Our approach to combating these pathogens is highly innovative, and I am looking forward to continuing to grow our organization’s expertise at developing these impactful medicines.”

About 3-V Biosciences
3-V Biosciences, Inc. is a privately held biopharmaceutical company dedicated to discovering, developing and ultimately commercializing novel antiviral therapeutics that target host cell factors required for viral infection, thereby avoiding many of the shortcomings of traditional pathogen directed approaches. The company is located in Menlo Park, California and is financed by The Column Group, Kleiner Perkins Caufield & Byers, and New Enterprise Associates. For additional information on 3-V Biosciences, please visit